ImmuneSpec offers a cutting-edge immunopeptidomics platform designed to accelerate and enhance the identification of immunogenic peptides. Utilizing a state-of-the-art mass spectrometry (MS)-based approach, our platform provides unparalleled accuracy and depth in profiling the peptide landscape presented by MHC molecules. 
By enabling the precise detection and characterization of these peptides, we empower life sciences, biotechnology companies, and CROs to accelerate the development of transformative therapies, including broad-spectrum vaccines, personalized medicine, and novel immunotherapeutics.

By offering a thorough and unbiased analysis of the immunopeptidome, we empower researchers to discover new targets, enhance known antigens, and detect rare, mutation-derived neoepitopes that are ideal candidates for biotherapeutics. Additionally, we identify immunogenic regions within biotherapeutics, helping to optimize their design and reduce potential immunogenicity, thereby improving safety and efficacy profiles.


Biotechnology

Life Sciences

Therapeutics

ImmuneSpec

ImmuneSpec's headquarters in Niel, Belgium

People (4)

Jobs (0)

Other offices